Century Therapeutics, Inc. · NASDAQ:IPSC
Century Therapeutics — Investor Presentation (September 2022)
23 slides from Century Therapeutics's investor presentation, Sep 8, 2022
Slide 1: Corporate Overview September 2022
Corporate Overview September 2022
Slide 2: Forward-looking statements
2 Forward - looking statements This presentation contains forward - looking statements within the meaning of, and made pursuant to the safe harbour provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this document, other than statements of historical fact
Slide 3: Emerging leader in cell therapies for cancer
Emerging leader in cell therapies for cancer Comprehensive iPSC cell platform For immune effector cells Technical Expertise Genetic and protein engineering, process development and immuno - oncology Foundation in Science Continuing investment in innovation drives R&D State - of - the - art GMP manuf
Slide 4: Proven leadership team
Osvaldo (Lalo) Flores CEO Adrienne Farid COO Greg Russotti CTO Hy Levitsky President R&D Luis Borges CSO Michael Diem CBO Proven leadership team ® 4
Slide 5: Platform
Platform
Slide 6: Building a next generation allogeneic cell therapy platform
6 Building a next generation allogeneic cell therapy platform Gene Editing • Proprietary gene editing platform • CRISPR MAD7 - derived gene editing for precise transgene integration Protein Engineering • Developing proprietary next - generation CARs • Universal tumor targeting platform iPSC Differen
Slide 7: Foundational investments in iPSC know-how and manufacturing
7 Foundational investments in iPSC know - how and manufacturing Established in - house manufacturing accelerates learnings and enables faster product iteration • 53,000 ft 2 facility • Designed to produce multiple immune cell types • Two sites provides optionality and maximizes flexibility iPSC lice
Slide 8: Multiple gene edits (KO/KI) iPSC bank
8 Multiple gene edits (KO/KI) iPSC bank Precision CRISPR MAD7 mediated sequential gene editing of iPSC cells generates uniform product candidates Engineered iPSC Master Cell Bank (MCB) Advantages of Century’s Platform P recise CRISPR mediated homology directed repair reduces off - target integration
Slide 9: Allo-Evasion 1.0 designed to overcome host vs graft rejection
9 Allo - Evasion TM 1.0 designed to overcome 3 major pathways of host vs graft rejection 1. Deletion of β 2M, a protein required to express HLA - 1 on the cell surface prevents recognition by CD8 T cells 2. Knock out of CIITA eliminates HLA - II expression to escape elimination by CD4 T cells 3. Kno
Slide 10: Allo-Evasion 3.0 Provides Additional Protection Against NK Cell Killing
10 Allo - Evasion TM 3.0 Provides Additional Protection Against NK Cell Killing 1. Deletion of β 2M, a protein required to express HLA - 1 on the cell surface prevents recognition by CD8 T cells 2. Knock out of CIITA eliminates HLA - II expression to escape elimination by CD4 T cells 3. Knock - in o
Slide 11: Expression of HLA-E + HLA-G further protects from NK cell killing
11 Expression of HLA - E + HLA - G further protects from NK cell killing HLA - E HLA - G NKG2A KIRs, LIRs Activating ligand Activating receptor Proof - of - Concept Study with HLA - I Null K562 Cells Engineered with HLA - E and HLA - G 0 . 1 2 5 0 . 2 5 0 . 5 1 2 4 8 1 6 3 2 0 20 40 60 80 100 Donor
Slide 12: Illustrative potential of Allo-evasion on cellular pharmacokinetics and multiple doses
12 Illustrative potential of Allo - evasion ۲ on cellular pharmacokinetics and multiple doses With Allo - Evasion TM engineering Initial dose Minimum threshold to maintain pharmacological pressure Repeat dose Repeat dose Without Allo - Evasion TM engineering Lack of durable responses seen to date in
Slide 13: Common progenitor milestone enables cost, time efficiencies
13 Common progenitor milestone enables cost, time efficiencies Multiple gene edits Engineered iPSC iNK cell iPSC bank Cell engineering Manufacturing Common Progenitor iNK 3.0 CD34 + HSC T cell Reprogramming Reprogramming Differentiation NK cell • iPSC cell bank with 12 core 3.0 gene edits introduced
Slide 14: Discovery
Discovery
Slide 15: iNK 3.0 common progenitor multiple new features for enhanced functionality
15 iNK 3.0 common progenitor multiple new features for enhanced functionality Tumor cell killing Allo - Evasion TM Cell Fitness Imaging + Cytokine support + Safety switch iNK CP Boldface : iNK 3.0 - specific gene edits Common Progenitor Features ENGINEERING PROFILE Step Gene Edit Rationale 1 KO NKG2
Slide 16: Century's strategic vision for winning in solid tumors
16 Century’s strategic vision for winning in solid tumors Building best - in - class γδ i T cell platform with up to 5 distinct tumor killing mechanisms CAR CD16 NKG2D Safety switch & tracer TCR UTRAP Tumor antigen/ TCR Stress ligands Antibody/tumor antigen ADCC Tumor antigen Non - HLA TCR target Cy
Slide 17: Pipeline and Franchises
Pipeline and Franchises
Slide 18: Century's emerging franchises
18 Century’s emerging franchises B cell malignancies CNTY - 101 : Lead product candidate, CD19 targeted CAR - iNK • F irst product candidate to enter the clinic with edits designed to avoid 3 major pathways of rejection CNTY - 102 : First gd iT candidate, multi - specific (CD19 + CD79b) CAR - iT Dis
Slide 19: Product candidate pipeline across cell platforms and targets
Product iPSC Platform Targets Indications Expected IND Submission Discovery Preclinical Clinical Collaborator CNTY - 101 iNK CD19 B - Cell Malignancies Mid 2022 CNTY - 103 iNK CD133 Glioblastoma 2024 CNTY - 102 iT CD19 + CD79b B - Cell Malignancies 2024 CNTY - 104 iNK / iT Multi - specific Acute Mye
Slide 20: ELiPSE-1: Phase 1 study vision
20 ELIPSE - 1: Phase 1 study vision CNTY - 101: differentiated next - gen CD19 targeted product CNTY - 101 First cell product candidate designed to avoid all major pathways of host v graft rejection Allo - Evasion TM edits Highly differentiated profile HLA - I Knockout IL - 15 HLA - II Knockout CD19
Slide 21: Century's partnered programs
21 Century’s partnered programs Acute Myeloid Leukemia CNTY - 104: Multi - specific iT or iNK candidate Potential for controlled dosing and persistence to eliminate blasts while mitigating toxicity to the marrow Multiple Myeloma CNTY - 106: Multi - specific iT or iNK candidate Address relapses to cu
Slide 22: Anticipated catalysts over next months
22 Anticipated catalysts over next 12 months Underpinned by strong balance sheet with platform synergies and operational excellence CNTY - 101 Becoming clinical stage biotech company with most advanced allogeneic cell therapy • Phase 1 (ELiPSE - 1) start in B - cell malignancies (2H22) γδ iT Platfor
Slide 23: Thank you
CENTURY Thank you
Century Therapeutics — Investor Presentation (September 2022) on 6ix